drugset
drugset / Trial / NCT01178346

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

NCT01178346 ↗

Phase 3 Completed 500 enrolled Nabi Biopharmaceuticals GlaxoSmithKline · collab
Non-randomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.

Timeline

Start
2010-07
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NicVAX Vaccine — —

Indications

No indication recorded.